

ASX Announcement

Appendix 3Y - Alan W. Dunton, MD

Sydney Australia, 11 December 2020: Recce Pharmaceuticals Ltd (**ASX: RCE**), the Company developing New Classes of Synthetic Anti-Infectives, advises that the attached Appendix 3Y reflects 60,000 fully paid ordinary shares were issued to Dr Dunton as part of his remuneration for his services to the Company as approved by shareholders at the Annual General Meeting held on 30 November 2020.

The Company notes that this notice includes a reference to additional 10,000 fully paid ordinary shares held by Dr Dunton. Dr Dunton purchased these 10,000 fully paid ordinary shares on market prior to being appointed as a Director of the Company. The initial Director Interest Notice lodged in respect of Dr Dunton's interest did not include details of these 10,000 fully paid ordinary shares due to an administrative oversight.

What additional steps has the Company taken, or does it intend to take, to ensure compliance with Listing Rules 3.19A and 3.19B?

The Company and Directors are aware of the requirements under ASX Listing Rules 3.19A and 3.19B. The Company has reinforced with the Directors the importance of accurate reporting as required under the current ASX requirements, and is confident that the processes it has in place will ensure compliance with Listing Rules 3.19A and 3.19B.

This announcement has been approved for release by the Company Secretary.



ASX: RCE

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 T +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ACN	124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Alan W Dunton
Date of last notice	14 July 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Danarius, LLC
Date of change	4 December 2020
No. of securities held prior to change	10,000 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	60,000 Fully Paid Ordinary Shares
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. 60,000 fully paid ordinary shares were issued to Dr Dunton as part of his remuneration for his services to the Company.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	70,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Fully Paid Ordinary Shares as approved by shareholders at the Annual General Meeting held on 30 November 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.